Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
- PMID: 32350860
- DOI: 10.1002/cpt.1877
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
Comment in
-
Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".Clin Pharmacol Ther. 2020 Aug;108(2):190. doi: 10.1002/cpt.1878. Epub 2020 May 21. Clin Pharmacol Ther. 2020. PMID: 32353191 Free PMC article. No abstract available.
Comment on
-
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21. Clin Pharmacol Ther. 2020. PMID: 32246834 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
